- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04922450
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
A Multi-center, Single-arm, Phase II Clinical Study of Camrelizumab in Combination With Albumin Paclitaxel and Cisplatin for Neoadjuvant Treatment of Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
연구 개요
상세 설명
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Yaqian Han
- 전화번호: 18673176667
- 이메일: hanyaqiancs@163.com
연구 장소
-
-
Hunan
-
Changsha, Hunan, 중국
- 모병
- Hunan Cancer Hospital
-
연락하다:
- Yaqian Han
- 전화번호: 18673176667
- 이메일: hanyaqiancs@163.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18-65 years, both men and women;
- Patients who diagnosed as Squamous cell carcinoma by pathological examination;
- Patients who have not received systemic or local treatment for head and neck squamous cell carcinoma;
- The primary tumor and lymph nodes can be completely surgically removed;
- Exclude distant metastasis through chest CT and full-body bone scanning;
- The patient's vital organs are functioning normally and can tolerate the specified treatment plan Absolute neutrophil count ≥1.8 × 109 / L platelets ≥100 × 109/L, Hemoglobin ≥9g/dL, serum albumin ≥3g/dL Bilirubin≤1.5 ULN ALT and AST≤2.5 ULN INR≤1.5 ULN leukocyte≥2000/L Serum creatinine ≤ 1.5 ULN Thyroid Stimulating Hormone≤ 1 ULN
- ECOG score:0-1
- Women of childbearing age (15-49 years old) have a negative serum or urine HCG test within 7 days before treatment, and agree to use medically approved measures for contraception during treatment and 120 days after treatment ends
- Males who have not been sterilized must agree to take effective contraceptive measures during the study period and at least 120 days after the last dose of PD-1 monoclonal antibody
- Patients can provide enough tissue samples for PD-L1 detection or exploratory research.
- The patient signs an informed consent and voluntarily participates in the clinical trial
Exclusion Criteria:
- Patients who pathologically confirmed non-squamous cell carcinoma
- Patients who has recurrence or distant metastasis
- Local lesions have been surgically removed
- Patients who have received systemic anti-cancer therapy, including hormone therapy
- Patients who have received treatment targeting PD-1 or PD-L1
Patients with active autoimmune disease or a history of autoimmune disease but may relapse(Patients with the following diseases are not excluded and can be further filtered)
- Controlled type 1 diabetes
- Hypothyroidism(If it can be controlled with hormone replacement therapy)
- Controlled celiac disease
- Skin diseases that do not require systemic treatment such as Vitiligo, Psoriasis and Hair loss.
- Any other disease that is not expected to recur without external triggers
- Any active malignant tumors within 2 years before treatment, except for the specific cancers being studied in this trial and locally recurring cancers that have been cured (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical in situ Cancer or breast cancer)
Any disease requiring systemic treatment with corticosteroids (referring to treatment with a dose higher than 10 mg/day of prednisone or equivalent doses of similar drugs) or other immunosuppressive treatments within 14 days before treatment.
However, patients who have currently or previously used any of the following steroid regimens can be selected:
- Adrenaline replacement steroids(Prednisone ≤10mg/day or equivalent dose of similar drugs)
- Local, ophthalmic, intra-articular, intranasal and inhaled corticosteroids which is Systemic absorbed Minimally
- Prophylactically short-term (≤7 days) use of corticosteroids (for example, allergy to contrast agents) or for the treatment of non-autoimmune conditions (for example, delayed hypersensitivity reactions caused by contact allergens)
- Uncontrolled diabetes within 14 days before treatment or laboratory abnormalities with potassium, sodium and corrected calcium levels> 1 after standard drug treatment or hypoalbuminemia grade ≥ 3
- History of the following diseases: interstitial lung disease, non-infectious pneumonia or uncontrollable diseases, including pulmonary fibrosis, acute lung disease, etc.
- Severe chronic or active infection (including tuberculosis infection, etc.) that required systemic antibiotics, antibacterial or antiviral treatment occurred within 14 days before the first administration of the study drug
- The patient is known to have been infected with HIV
Untreated patients with chronic hepatitis B or HBV carriers with chronic hepatitis B virus (HBV) DNA ≥ 500 IU/mL or active hepatitis C virus carriers (HCV) should be excluded.
Patients can be selected who is Inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA <500 IU/mL) and cured hepatitis C patients.
- Any surgery requiring general anesthesia has been performed within 28 days before treatment
- Have had allogeneic stem cell transplantation or organ transplantation
Have any of the following cardiovascular risk factors:
- Cardiogenic chest pain within 28 days before treatment(moderate pain that restricts instrumental activities of daily living)
- Symptomatic pulmonary embolism within 28 days before treatment
- Acute myocardial infarction within 6 months before treatment
- Any history of heart failure that has reached Grade III or IV as defined by the New York Heart Association within 6 months before treatment
- Grade 2 ventricular arrhythmia within 6 months before the first administration of the study drug
- Have a history of cerebrovascular accident within 6 months before the first administration of the study drug
- Have a history of severe hypersensitivity to other monoclonal antibodies
- Patients with treatment toxicity (caused by previous anti-cancer treatments) have not returned to baseline or stabilized, unless it is an AE that is not considered a possible safety risk (such as hair loss, neuropathy, or specific laboratory abnormalities)
- History of allergic reactions to cisplatin or other platinum-containing compounds
- Peripheral nerve disease ≥ Grade 2 defined by NCI CTCAE v5.0 standard Have gotten a live vaccine within 4 weeks before treatment(Seasonal flu vaccines are usually inactivated vaccines and are allowed to be used; The vaccine used in the nasal cavity is a live vaccine and is not allowed to be used)
- Abuse or dependence on alcohol or drugs and Basic medical conditions (including laboratory abnormalities) that are not conducive to the administration of the study drug , affect the interpretation of drug toxicity or AEs, lead to insufficient compliance with the study execution and possible damage
- The patient participates in another therapeutic clinical study at the same time
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Camrelizumab,albumin paclitaxel and cisplatin.
Participants will be given intravenous administration of Camrelizumab (200mg),Albumin Paclitaxel(260mg/m²) and Cisplatin(80mg/m²),After completing three times every three weeks of neoadjuvant therapy, The Participants will undergo surgery and Postoperative intensity modulated chemotherapy.
The duration of treatment will till death, or unacceptable toxicity show up.
|
Intravenous administration of SHR1210 (200mg/3weeks)
Albumin Paclitaxel(260mg/m²),every 3 weeks
Cisplatin(80mg/m²), every 3 weeks
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Clinical remission rate(CRR)
기간: immediately after the surgery
|
the short-term efficacy of Camrelizumab combined with albumin paclitaxel/cisplatin neoadjuvant treatment of operable locally advanced head and neck cancer
|
immediately after the surgery
|
Pathological remission rate(PRR)
기간: immediately after the surgery
|
the short-term efficacy of Camrelizumab combined with albumin paclitaxel/cisplatin neoadjuvant treatment of operable locally advanced head and neck cancer
|
immediately after the surgery
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
2-year survival rate, 2-year progression-free survival rate, 2-year recurrence-free survival rate, 2-year survival rate without distant metastasis
기간: 2 year
|
1. the long-term efficacy of Camrelizumab combined with albumin paclitaxel/cisplatin neoadjuvant treatment of operable locally advanced head and neck cancer
|
2 year
|
Adverse event rate
기간: 2 year
|
The safety of Camrelizumab combined with albumin paclitaxel/cisplatin neoadjuvant treatment of operable locally advanced head and neck cancer
|
2 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Yaqian Han, Hunan Cancer Hospital
- 수석 연구원: Wenxiao Huang, Hunan Cancer Hospital
- 수석 연구원: Hui Wang, Hunan Cancer Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HNIC21
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 기간
IPD 공유 액세스 기준
IPD 공유 지원 정보 유형
- 연구_프로토콜
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
PD-1 inhibitor에 대한 임상 시험
-
Medical College of Wisconsin종료됨
-
RWJ Barnabas Health at Jersey City Medical Center알려지지 않은
-
Tongji HospitalNational Natural Science Foundation of China모병
-
Instituto Nacional de Cancerologia de Mexico알려지지 않은
-
University of Colorado, DenverNational Cancer Institute (NCI); Cancer League of Colorado빼는
-
The First Affiliated Hospital of Guangdong Pharmaceutical...University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co., Ltd.알려지지 않은